281 related articles for article (PubMed ID: 34081788)
21. Interleukin-6, CXCL10 and Infiltrating Macrophages in COVID-19-Related Cytokine Storm: Not One for All But All for One!
Coperchini F; Chiovato L; Rotondi M
Front Immunol; 2021; 12():668507. PubMed ID: 33981314
[TBL] [Abstract][Full Text] [Related]
22. Role of Host Immune and Inflammatory Responses in COVID-19 Cases with Underlying Primary Immunodeficiency: A Review.
Liu BM; Hill HR
J Interferon Cytokine Res; 2020 Dec; 40(12):549-554. PubMed ID: 33337932
[TBL] [Abstract][Full Text] [Related]
23. SARS-CoV-2 multifaceted interaction with the human host. Part II: Innate immunity response, immunopathology, and epigenetics.
Beacon TH; Su RC; Lakowski TM; Delcuve GP; Davie JR
IUBMB Life; 2020 Nov; 72(11):2331-2354. PubMed ID: 32936531
[TBL] [Abstract][Full Text] [Related]
24. Mast cells activated by SARS-CoV-2 release histamine which increases IL-1 levels causing cytokine storm and inflammatory reaction in COVID-19.
Conti P; Caraffa A; Tetè G; Gallenga CE; Ross R; Kritas SK; Frydas I; Younes A; Di Emidio P; Ronconi G
J Biol Regul Homeost Agents; 2020 Sep-Oct,; 34(5):1629-1632. PubMed ID: 32945158
[TBL] [Abstract][Full Text] [Related]
25. Coronavirus-19 (SARS-CoV-2) induces acute severe lung inflammation via IL-1 causing cytokine storm in COVID-19: a promising inhibitory strategy.
Conti P; Caraffa A; Gallenga CE; Ross R; Kritas SK; Frydas I; Younes A; Ronconi G
J Biol Regul Homeost Agents; 2020; 34(6):1971-1975. PubMed ID: 33016027
[TBL] [Abstract][Full Text] [Related]
26. Autoinflammatory Diseases and Cytokine Storms-Imbalances of Innate and Adaptative Immunity.
Marcuzzi A; Melloni E; Zauli G; Romani A; Secchiero P; Maximova N; Rimondi E
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681901
[TBL] [Abstract][Full Text] [Related]
27. [The neurology of COVID-19].
Cuevas-García C; Calderón-Vallejo A; Berrón-Ruiz L
Rev Alerg Mex; 2020; 67(4):338-349. PubMed ID: 33631902
[TBL] [Abstract][Full Text] [Related]
28. CCR2 Signaling Restricts SARS-CoV-2 Infection.
Vanderheiden A; Thomas J; Soung AL; Davis-Gardner ME; Floyd K; Jin F; Cowan DA; Pellegrini K; Shi PY; Grakoui A; Klein RS; Bosinger SE; Kohlmeier JE; Menachery VD; Suthar MS
mBio; 2021 Dec; 12(6):e0274921. PubMed ID: 34749524
[TBL] [Abstract][Full Text] [Related]
29. Minor Clinical Impact of COVID-19 Pandemic on Patients With Primary Immunodeficiency in Israel.
Marcus N; Frizinsky S; Hagin D; Ovadia A; Hanna S; Farkash M; Maoz-Segal R; Agmon-Levin N; Broides A; Nahum A; Rosenberg E; Kuperman AA; Dinur-Schejter Y; Berkun Y; Toker O; Goldberg S; Confino-Cohen R; Scheuerman O; Badarneh B; Epstein-Rigbi N; Etzioni A; Dalal I; Somech R
Front Immunol; 2020; 11():614086. PubMed ID: 33519822
[TBL] [Abstract][Full Text] [Related]
30. Multivariate analysis of factors associated with early-onset segmental and nonsegmental vitiligo: a prospective observational study of 213 patients.
Ezzedine K; Diallo A; Léauté-Labrèze C; Mossalayi D; Gauthier Y; Bouchtnei S; Cario-André M; Seneschal J; Boralevi F; Jouary T; Taieb A
Br J Dermatol; 2011 Jul; 165(1):44-9. PubMed ID: 21410675
[TBL] [Abstract][Full Text] [Related]
31. Age-related differences in the immune response could contribute to determine the spectrum of severity of COVID-19.
Costagliola G; Spada E; Consolini R
Immun Inflamm Dis; 2021 Jun; 9(2):331-339. PubMed ID: 33566457
[TBL] [Abstract][Full Text] [Related]
32. Autoimmune complications of COVID-19.
Yazdanpanah N; Rezaei N
J Med Virol; 2022 Jan; 94(1):54-62. PubMed ID: 34427929
[TBL] [Abstract][Full Text] [Related]
33. COVID-19 vaccine-associated vitiligo: A cross-sectional study in a tertiary referral center and systematic review.
Tsai TF; Ng CY
J Dermatol; 2023 Aug; 50(8):982-989. PubMed ID: 37186102
[TBL] [Abstract][Full Text] [Related]
34. Autoimmunity in Segmental Vitiligo.
Speeckaert R; Lambert J; Bulat V; Belpaire A; Speeckaert M; van Geel N
Front Immunol; 2020; 11():568447. PubMed ID: 33193342
[TBL] [Abstract][Full Text] [Related]
35. Understanding autoimmunity of vitiligo and alopecia areata.
Rork JF; Rashighi M; Harris JE
Curr Opin Pediatr; 2016 Aug; 28(4):463-9. PubMed ID: 27191524
[TBL] [Abstract][Full Text] [Related]
36. Implications of Low-grade Inflammation in SARS-CoV-2 Immunopathology.
Suárez-Reyes A; Villegas-Valverde CA
MEDICC Rev; 2021 Apr; 23(2):42. PubMed ID: 33974614
[TBL] [Abstract][Full Text] [Related]
37. Cyclosporine A Inhibits Viral Infection and Release as Well as Cytokine Production in Lung Cells by Three SARS-CoV-2 Variants.
Fenizia C; Galbiati S; Vanetti C; Vago R; Clerici M; Tacchetti C; Daniele T
Microbiol Spectr; 2022 Feb; 10(1):e0150421. PubMed ID: 34985303
[TBL] [Abstract][Full Text] [Related]
38. Severe immunosuppression and not a cytokine storm characterizes COVID-19 infections.
Remy KE; Mazer M; Striker DA; Ellebedy AH; Walton AH; Unsinger J; Blood TM; Mudd PA; Yi DJ; Mannion DA; Osborne DF; Martin RS; Anand NJ; Bosanquet JP; Blood J; Drewry AM; Caldwell CC; Turnbull IR; Brakenridge SC; Moldwawer LL; Hotchkiss RS
JCI Insight; 2020 Sep; 5(17):. PubMed ID: 32687484
[TBL] [Abstract][Full Text] [Related]
39. Defying convention in the time of COVID-19: Insights into the role of γδ T cells.
Sanz M; Mann BT; Chitrakar A; Soriano-Sarabia N
Front Immunol; 2022; 13():819574. PubMed ID: 36032159
[TBL] [Abstract][Full Text] [Related]
40. Cytokine Storm: The Primary Determinant for the Pathophysiological Evolution of COVID-19 Deterioration.
Chen R; Lan Z; Ye J; Pang L; Liu Y; Wu W; Qin X; Guo Y; Zhang P
Front Immunol; 2021; 12():589095. PubMed ID: 33995341
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
